Our understanding of schizophrenia has increased greatly in recent years, as studies of large groups of people have identified a multitude of genetic variants that increase a person's risk of the ...

A finding by a McGill-led team of neuroscientists could open doors to new treatments for a range of psychiatric and neurological disorders attributed to dysfunctions in specific dopamine pathways. For ...

The placebo effect can have a significant influence on treatment outcomes. While we still have a lot to learn about how and why a patient’s expectations can influence the effectiveness of medication ...

Prof. Alex Nord, right and graduate student Tracy Warren have discovered genetic variants linked to some symptoms of schizophrenia that are currently hard to treat. The work could lead to new insights ...

Dopamine is one of the most extensively studied chemical messengers in the human brain, and yet scientists are still figuring out how it works to accomplish so much. For years, the classic view has ...

A McGill University-led study found that people with cannabis use disorder (CUD) had elevated dopamine levels in a brain region associated with psychosis. “This could help explain why cannabis use ...

No new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...